Dario Scimeca, an officer at Precision BioSciences, has filed a notice to sell 2,821 shares of the company’s common stock. This transaction, valued at approximately $27,516.91, is significant as it reflects the ongoing activities of company insiders and may influence investor sentiment.

Precision BioSciences, Inc. is a company incorporated in Delaware, primarily engaged in the development of biological products. The company is listed on the NASDAQ under the SEC file number 001-38841. The recent filing, dated November 10, 2026, is part of the company's ongoing disclosures to the SEC.

According to the filing, Scimeca’s shares were acquired through an Employee Stock Purchase Plan (ESPP), with the most recent purchases made on various dates, including February 28, 2020, and August 31, 2020. The filing states, "The nature of the acquisition transaction was ESPP Purchase," indicating that these shares were obtained as part of an employee benefit program.

This sale may affect investor perceptions of Precision BioSciences, particularly in the context of insider trading activity. The company operates within the biological products sector, which is characterized by intense competition and innovation. The filing does not specify any further actions or upcoming events related to this sale.

Details were not available in the SEC filing regarding any future transactions or company announcements following this sale.